IL2RA and neoplasm: To ensure the targeted depletion of tumor-associated Tregs while avoiding immune-related side effects due to systemic Treg cytopenia, a specific selective CD25 blocker (RG6292) has been developed which enhances antitumor activity without significant immune-related toxicity [189].